A Gene Expression Profile of BRCAness That Predicts for Responsiveness to Platinum and PARP Inhibitors
Technical Report,15 Jul 2014,14 Jul 2015
Dana Farber Cancer Institute Boston United States
Pagination or Media Count:
In this annual progress report of the work performed from 7152014 to 7142015, we ipresent data on a unique subset of ovarian cancers which are not BRCA like, i.e. not HR deficient and are resistant to PARPis but are sensitive to platinum. These tumors exhibit alterations in another DNA repair pathway called nucleotide excision repair NER pathway. iipresent data that HSP90-inhibitors which were identified via our BRCAness profile may sensitize PARPi-resistant xenograft models to PARPis. iiiupdate our progress on validating our profile in a cohort of molecularly defined BRCA-mutated and HR-proficient tumors.